GlassScriptPhysician profile
Jay B Stambler
NPI 1821029026
$6,943.52
in general payments reported to CMS, 2019-2025
37 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,888 · 2020: $747 · 2021: $1,514 · 2022: $1,209 · 2023: $772 · 2024: $323 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,585.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,658.38 | 2019-2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $1,187.83 | 2020-2023 | |
| Abbvie INC. | $892.42 | 2019-2025 | Linzess, Viberzi, Mavyret |
| Novo Nordisk INC | $383.28 | 2019-2024 | Wegovy |
| Ferring Pharmaceuticals INC. | $280.60 | 2019-2023 | Rebyota |
| Amarin Pharma, INC. | $229.52 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $225.84 | 2021-2025 | Lokelma, Airsupra |
| Lilly USA, LLC | $223.26 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Daiichi Sankyo INC. | $214.86 | 2019-2023 | Injectafer |
| Pfizer INC. | $211.44 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $203.72 | 2019-2020 | |
| Gilead Sciences, INC. | $105.10 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $92.93 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $92.17 | 2019-2020 | |
| Amgen INC. | $88.31 | 2019-2023 | Prolia, Evenity |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Stambler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.